Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carlecortemcel-l
- Development stage
- Phase 3
- Lead developer
- Gamida Cell
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Carlecortemcel-l is an ex vivo expanded umbilical cord blood cell therapy developed for hematopoietic stem cell transplantation in patients with high-risk hematologic malignancies. The product consists of a graft of expanded stem/progenitor cells derived from part of a single unit of umbilical cord blood, which is transplanted intravenously along with the remaining unmanipulated fraction. The expansion process uses cytokines and the copper chelator tetraethylenepentamine to increase the number of CD34+ hematopoietic stem cells without promoting differentiation. This approach aims to improve engraftment rates and early survival following transplantation compared to standard double-unit cord blood transplants. Clinical studies have shown that carlecortemcel-l can facilitate faster neutrophil and platelet engraftment and may be associated with improved 100-day survival rates in recipients[3][4][5][7]. The drug was initially developed by Gamida Cell in collaboration with Teva Pharmaceutical Industries.
- Brand names
- StemEx
- Other names
- carlecortemcel-lStemEx
Beyond the preview
Go deeper on carlecortemcel-l.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carlecortemcel-l.